Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population

Abstract

ObjectiveTo evaluate the diagnostic value of fluorescence in situ hybridization (FISH) in bladder cancer.MethodsWe enrolled healthy volunteers and patients who were clinically suspected to have bladder cancer and conducted FISH tests and cytology examinations from August 2007 to December 2008. Receiver operating characteristic (ROC) curve analysis was performed and the area under curve (AUC) values were calculated for both the FISH and urine cytology tests.ResultsA cohort of 988 healthy volunteers was enrolled to establish a reference range for the normal population. A total of 4807 patients with hematuria were prospectively, randomly enrolled for the simultaneous analysis of urine cytology, FISH testing, and a final diagnosis as determined by the pathologic findings of a biopsy or a surgically-excised specimen. Overall, the sensitivity of FISH in detecting transitional-cell carcinoma was 82.7%, while that of cytology was 33.4% (p < 0.001). The sensitivity values of FISH for non-muscle invasive and muscle invasive bladder transitional-cell carcinoma were 81.7% and 89.6%, respectively (p = 0.004). The sensitivity values of FISH for low and high grade bladder cancer were 82.6% and 90.1%, respectively (p = 0.002).ConclusionFISH is significantly more sensitive than voided urine cytology for detecting bladder cancer in patients evaluated for gross hematuria at all cancer grades and stages. Higher sensitivity using FISH was obtained in high grade and muscle invasive tumors.

Diagnostic accuracy of NMP 22 and urine cytology for detection of transitional cell carcinoma urinary bladder taking cystoscopy as gold standard

“…Zhou L et al23 are comparable to our results (30%, 91% & 86%). Another study conducted by Bier S. et al24 included 758 bladders and 385 upper urinary tract (UUT) samples, the sensitivity of cytology & NMP 22 were found 74.6 & 100% for UUT and 59.3 & 62.5% for bladder samples while specificity was 66.6 & 50.9% for UUT and 82.9 & 31.3 for bladder samples.…”

Evaluation of UroVysion for Urachal Carcinoma Detection

“…The chromosome 9p21 region (p16) gene deletion rate was only 14.29% (1/7). However, in a multicenter big data study conducted by Zhou et al ( 10 ) in China, the polysomy of chromosomes 3, 7, and 17 and gene changes at 9p21 region (p16) accounted for 71.3% (2941/4125), 72.2% (2978/4125), 67.4% (2780/4125), and 72.9% (3007/4125) of urothelial carcinoma cases, respectively. Therefore, the chromosome 9p21 region (p16) gene deletion in urachal carcinoma seems to occur less frequently than in urothelial carcinoma (16.67 vs. 72.9%, P = 0.008).…”

“…Numerous studies have evaluated the efficacy of FISH in urothelial carcinoma ( 5 – 10 ), whereas data on the evaluation of UroVysion probes in non-urothelial carcinoma are scarce. This study found that the positive rate of FISH in urachal carcinoma of late stage with hematuria was rather high at 71.43%, which was not significantly different from that in urothelial carcinoma (71.43 vs. 87.18%, P = 0.245).…”

“…This method has been approved for the screening of patients with hematuria and the monitoring of recurrent urothelial carcinoma. Moreover, many studies have been performed using the application of FISH in urothelial carcinoma ( 5 – 10 ). Thus, patients with hematuria who are positive for urinary FISH are often diagnosed with urothelial carcinoma.…”

A Mini Review on Epigenetics MiRNAs and their Influence on Bladder Cancer Development

“…With fluorescence in situ hybridization (FISH) techniques, chromosomal anomalies can be detected in exfoliated bladder cells. Several studies reported low sensitivity of FISH to detect low-grade (36%-57%) and low-stage (62%-65%) tumors, while has high sensitivity for both high-grade and high-stage tumors (83%-97%) [4,5]. The detection of CIS is close to 100% and its hight specificity (89%-96%) is comparable to cytology [6].…”